Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient

A 50‐year‐old woman with stage IV lung adenocarcinoma received seven cycles of pembrolizumab as third‐line chemotherapy. Following the failure of pembrolizumab, she commenced fourth‐line chemotherapy of docetaxel and ramucirumab. The patient complained of epigastric pain and a computed tomography (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Sachiko, Watanabe, Keisuke, Kobayashi, Nobuaki, Irie, Kuniyasu, Yamanaka, Shoji, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148160/
https://www.ncbi.nlm.nih.gov/pubmed/32284868
http://dx.doi.org/10.1002/rcr2.560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148160/
https://www.ncbi.nlm.nih.gov/pubmed/32284868
http://dx.doi.org/10.1002/rcr2.560

Ejemplares similares